Bluebird Bio

bluebird bio is a clinical-stage biotechnology company committed to developing potentially transformative gene therapies for severe genetic diseases and cancer. The company's clinical programs in severe genetic diseases include its LentiGlobin? product candidate as a treatment for transfusion-dependent ß-thalassemia, and severe sickle cell disease, or severe SCD, and its Lenti-D? product candidate as a treatment for cerebral adrenoleukodystrophy, a rare hereditary neurological disorder. bb2121 and bb21217, the company's primary product candidates in oncology, are CAR T cell product candidates for the treatment of multiple myeloma.
  • TickerBLUE
  • ISINUS09609G1004
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for BLUE

ValuEngine Rating and Forecast Report for BLUE

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

EHA Abstract Roundup for Covered Companies

David Nierengarten ...
  • Jeffrey La Rosa

Downgrading to NEUTRAL; Can This Bird Fly Above the Launch Blues?

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

EHA Abstract Roundup for Covered Companies

David Nierengarten ...
  • Jeffrey La Rosa

Downgrading to NEUTRAL; Can This Bird Fly Above the Launch Blues?

1 director sold after exercising options/sold

A director at Bluebird Bio Inc sold after exercising options/sold 1,800 shares at 157.601USD and the significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under lis...

ValuEngine Rating and Forecast Report for BLUE

ValuEngine Rating and Forecast Report for BLUE

ValuEngine Rating and Forecast Report for BLUE

ValuEngine Rating and Forecast Report for BLUE

ValuEngine Rating and Forecast Report for BLUE

ValuEngine Rating and Forecast Report for BLUE

ValuEngine Rating and Forecast Report for BLUE

ValuEngine Rating and Forecast Report for BLUE

BLUEBIRD BIO sees a downgrade to Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of BLUEBIRD BIO (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date April 16, 2019, the closing price was USD 154.02 and its target price was estimated at USD 111.31.

MarketLine Department

CRISPR Therapeutics - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's CRISPR Therapeutics Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by CRISPR Therapeutics since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. ...

MarketLine Department

Sorrento Therapeutics, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Sorrento Therapeutics, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Sorrento Therapeutics, Inc. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competi...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • John Betz

Vermilion Compass: Weekly Equity Strategy

• Bullish but selective. As we alluded to last week, our long-term bullish outlook remains intact. However, looking through the charts we find a growing list of extended and parabolic patterns. While we continue to remain bullish, we acknowledge the likelihood of backing and filling, or a pause, is building. The further a stock's price action moves from its 200-day, the greater the possibility of a corrective reversion to the mean, or pullback. In last week's Compass our example was Boeing Corporation (BA). The stock is trading 40% above its 200-day moving average, and this rate of momentum i...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch